Market capitalization | $421.64m |
Enterprise Value | $392.14m |
P/E (TTM) P/E ratio | 292.06 |
EV/FCF (TTM) EV/FCF | 98.78 |
EV/Sales (TTM) EV/Sales | 4.28 |
P/S ratio (TTM) P/S ratio | 4.60 |
P/B ratio (TTM) P/B ratio | 12.21 |
Revenue growth (TTM) Revenue growth | 9.95% |
Revenue (TTM) Revenue | $91.67m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a ChromaDex Corporation forecast:
4 Analysts have issued a ChromaDex Corporation forecast:
Sep '24 |
+/-
%
|
||
Revenue | 92 92 |
10%
10%
|
|
Gross Profit | 56 56 |
13%
13%
|
|
EBITDA | 5.15 5.15 |
285%
285%
|
EBIT (Operating Income) EBIT | 3.65 3.65 |
180%
180%
|
Net Profit | 1.49 1.49 |
123%
123%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Chromadex Corp. is a nutraceutical company. The firm engages in acquiring, developing and commercializing proprietary-based ingredient technologies. It operates through the following segments: Ingredients, Consumer Products, and Analytical Reference Standards and Services. The Ingredients segment offers NIAGEN in an ingredient form to partners. The Consumer Products segment sells TRU NIAGEN to improve health by safely raising NAD levels. The Analytical Reference Standards and Services segment provides product regulatory approval and scientific advisory services to the clients in the food, supplement, and pharmaceutical industries. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in September 1999 and is headquartered in Los Angeles, CA.
Head office | United States |
CEO | Robert Fried |
Employees | 106 |
Founded | 1999 |
Website | www.chromadex.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.